Molecular Imaging in Neurological Disorders

PDFPrintE-mail

Known as a world leader in imaging Alzheimer disease and Parkinson disease imaging research, MNI provides clinical imaging services for trials related to a broad range of neuropsychiatric conditions.



Molecular imaging (PET/SPECT) is a powerful tool for identifying markers of understanding disease, identifying biomarkers, and developing novel therapeutics. MNI is a world leader in conducting molecular imaging studies in brain disease including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, post-traumatic stress disorder, traumatic brain injury, Huntington’s disease, Down  syndrome, neuropsychiatric conditions and other human diseases. The MNI clinical research team offers full-service design and implementation of early phase clinical trials.  Our clinical research team consists of physician investigators with expertise in Neurology, Psychiatry and Nuclear Medicine, clinical research nurse coordinators, neuropsychologists and imaging technologists.  MNI clinical researchers have a strong track record in designing, recruiting, and administering these trials, from Phase 1 to 4.

MNI capabilities include:

  • Develop and conduct early phase clinical imaging studies evaluating target-specific radioligands as diagnostic tools, markers of disease progression and evaluation of target occupancy for potential therapeutics
  • Proficient in medical writing and consulting services for regulatory documents including  Protocols, INDs, Study Reports
  • Develop modelling and provide expert imaging analysis to support studies in healthy controls or subjects with neuropsychiatric diseases
  • Clinical and imaging project management services to support single and multi-site trials in Phase 1-4 development.
  • Provide cGMP tracer manufacturing to support PET/SPECT research and support clinical development, including distribution to multi-site trials

In addition, consultation services are available to support imaging in neuropsychiatric conditions:

  • Radiotracer validation
  • Biomarker assessment
  • Early disease detection and diagnosis
  • Disease progression
  • Drug dosing and development